GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2009

DNDi to Search Pfizer’s Chemical Library for Potential HAT, VL, and Chagas Disease Treatments

  • The Drugs for Neglected Diseases initiative (DNDi) has gained access to the Pfizer library of novel chemical entities. DNDi will screen the compounds for their potential to be developed into new treatments for human African trypanosomiasis (HAT), visceral leishmaniasis (VL), and Chagas disease.

    Under the agreement, scientists in institutes affiliated with DNDi will test at least 150,000 compounds in the Pfizer library against Trypanosoma brucei, Leishmania donovani, and Trypanosoma cruzi, the parasites that cause HAT, VL, and Chagas disease, respectively. Researchers will seek compounds that show initial activity against the various parasites.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Mindclones and Immortality

Is the idea of making a software copy of a human mind something in the realm of reality or science fiction?